Isorhamnetin.

Isorhamnetin is the 3'-O-methyl metabolite that catechol-O-methyltransferase forms from quercetin in the enterocyte and liver. Dosing quercetin raises circulating isorhamnetin, so the two occupy the same metabolic pool.

Isorhamnetin is one of the three flavonol aglycones, with quercetin and kaempferol, that standardised ginkgo extract is assayed against. The flavonol glycosides in the extract hydrolyse to release it.

Sea buckthorn is one of the richest dietary sources of isorhamnetin glycosides, which the gut hydrolyses to the aglycone. Pairing the isolate with the whole fruit extract delivers the same flavonol in both free and glycoside form.

Ascorbate reduces the flavonoid phenoxyl radical formed after a flavonol donates a hydrogen atom, returning it to the active form. This recycling is why ascorbate and flavonols are routinely formulated together.

Piperine inhibits UDP-glucuronosyltransferase and sulfotransferase activity in the gut wall, the same enzymes that clear flavonols within minutes of absorption. Slowing conjugation raises the circulating unconjugated fraction.

Flavonoids compete for the same limited glucuronidation and sulfation capacity in the intestinal wall, so co-dosing raises the unconjugated exposure of each. The competition is a recognised flavonoid class effect.

Flavonols activate Nrf2 signalling, which raises transcription of the glutathione synthesis enzymes, and that pathway can only deliver if cysteine is available. NAC supplies the rate-limiting amino acid the upregulated enzymes need.

Flavonols carry catechol and hydroxyl groups that bind ferric iron in the gut lumen and hold it in a form the enterocyte cannot take up. Taking a flavonol with a non-heme iron dose lowers the absorbed fraction, so separating them by a couple of hours is the usual answer.

Polyphenol hydroxyl groups complex divalent cations including zinc in the intestinal lumen. Large flavonoid doses taken with a mineral dose can lower how much of the mineral is available for uptake.

Isorhamnetin is quercetin carrying a methyl group on the 3' position of the B ring. That methyl comes from S-adenosylmethionine, handed over by catechol-O-methyltransferase during first-pass metabolism of dietary quercetin. Methyl-donor status therefore sits upstream of how much isorhamnetin a person makes from a quercetin-rich meal or supplement. This is metabolic pathway chemistry, not a tested clinical pairing.

COMT holds a divalent magnesium ion in its active site to position the catechol hydroxyl for methyl transfer. Without that cofactor the methylation step does not run. The relationship is a cofactor requirement of the pathway that generates isorhamnetin, and it says nothing about supplemental magnesium changing isorhamnetin levels in people.

Rutin is quercetin-3-O-rutinoside and narcissin is the same sugar attached to isorhamnetin, so plant tissues that build one usually carry the other. A botanical source standardised on rutin will normally deliver some isorhamnetin glycoside as well. The evidence here is plant compositional analysis, not a human co-supplementation trial.

Rhamnosides resist human intestinal enzymes and pass to the colon, where bacterial glycosidases release the flavonoid. Which organisms are present changes how much free isorhamnetin appears and where along the gut it appears. This is a general feature of flavonol glycoside handling rather than a result from a trial pairing a named strain with isorhamnetin.

Quercetin's free catechol can oxidise to a reactive quinone that glutathione traps. Methylation of one hydroxyl, which is what makes isorhamnetin, blunts that chemistry, so isorhamnetin is expected to draw less on glutathione than its parent does. The interaction is chemical rather than clinical, and no human trial in this set measured glutathione alongside isorhamnetin.

Flavonols can donate a hydrogen atom to a tocopheroxyl radical at the membrane surface, a regeneration step shown for this chemical class in model systems. Isorhamnetin's methylated B ring makes it less reactive than quercetin in that role. This is interface chemistry measured in models, not a demonstrated outcome in people.

Both compounds participate in radical-scavenging chemistry, and lipoic acid works in both water and lipid phases where the flavonol is interface-bound. The pairing is chemically coherent and thinly studied. No human data in this candidate set tested them together.

Isorhamnetin aglycone is lipophilic and disperses poorly in water, which limits how much dissolves in intestinal fluid. Phospholipid complexes and lecithin-based dispersions are a standard formulation answer for this class of molecule. The claim is about the formulation approach, not about a measured plasma level for isorhamnetin specifically.

Taking a lipophilic flavonol with fat triggers bile release and micelle formation, which is how poorly soluble molecules cross the unstirred water layer. The general principle is well established for fat-soluble compounds. For isorhamnetin specifically it is an inference from physical chemistry, not a pharmacokinetic result.

EGCG is a heavy COMT substrate and competes for the same methylation and conjugation capacity that processes quercetin into isorhamnetin. Loading one polyphenol class can shift the metabolite mix of another. Direction and size of that shift in people has not been measured for this pair, so read it as a shared-pathway caution rather than a benefit.